Compared to older children and adolescents very young patients with type 1 diabetes represent a unique population. We analyzed the age-dependent characteristics and parameters of continuous subcutaneous insulin infusion (CSII) in children under 6 years of age with type 1 diabetes.
Methods:
We evaluated metabolic control and pump-dependent characteristics in 46 children with type 1 diabetes after 0.89 ± 0.62 years of CSII.
Results:
Metabolic control significantly improved after CSII initiation (glycosylated hemoglobin, 8.12 ± 1.24% vs. 7.30 ± 0.67%; P < 0.05), without increased risk for diabetic ketoacidosis or hypoglycemia. Interestingly, very young patients required bigger boluses than expected, especially in the morning and at the afternoon snack.
Conclusions:
These data support the need to personalize pump-dependent characteristics, especially in very young children with type 1 diabetes, in order to optimize CSII therapy in this unique age group of patients.
Get full access to this article
View all access options for this article.
References
1.
The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr, 1994; 125:177–188.
2.
PankowskaE, BlazikM, DziechciarzP, SzypowskaA, SzajewskaH. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systemic review and meta-analysis of randomized control trials. Pediatr Diabetes, 2009; 10:52–58.
3.
FoxLA, BucklohLM, SmithSD, WysockiT, MaurasN. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care, 2005; 28:1277–1281.
4.
EugsterEA, FrancisG. Lawson-Wilkins Drug and Therapeutics Committee. Position statement: continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics, 2006; 118:e1244–e1249.
5.
PhillipM, BattelinoT, RodriguezH, DanneT, KaufmanF. Use of insulin pump therapy in the pediatric age-group. Diabetes Care, 2007; 30:1653–1662.
6.
AhernJAH, BolandEA, DoaneR, AhernJJ, RoseP, VincentM, TamborlaneWV. Insulin pump therapy in paediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes, 2002; 3:10–15.
7.
WilsonDM, BuckinghamBA, KunselmanEL, SullivanMM, PaguntalanHU, GitelmanSE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care, 2005; 28:15–19.
PinelliL, RabboneI, SalardiS, ToniS, ScaramuzzaA, BonfantiR, CherubiniV, FranzeseA, FrongiaAP, IafuscoD, SulliN, TuminiS, CurtoO, MassimelliM. Diabetes Study Group of Italian Society of Paediatric Endocrinology and Diabetology. Insulin pump therapy in children and adolescents with type 1 diabetes: the Italian viewpoint. Acta Biomed, 2008; 79:57–65.
10.
DiMeglioLA, PottorffTM, BoydSR, FranceL, FinebergN, EugsterEA. A randomized controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr, 2004; 145:380–384.
11.
WeinzimerSA, AhernJH, DoyleEA, VincentMR, DziuraJ, SteffenAT, TamborlaneWV. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics, 2004; 114:1601–1605.
12.
RabboneI, BobbioA, BergerK, TradaM, SacchettiC, CeruttiF. Age-related differences in metabolic response to continuous subcutaneous insulin infusion in pre-pubertal and pubertal children with type 1 diabetes mellitus. J Endocrinol Invest, 2007; 30:477–483.
13.
JovanovičL. Intensified Insulin Delivery-Course Syllabus, San Diego, CA, 2005. Jacksonville, FL: American Association of Clinical Endocrinology, 2005.
14.
KordonuriO, HartmannR, LauterbornR, BarnekowC, HoeffeJ, DeissD. Age-specific advantages of continuous subcutaneous insulin infusion as compared with multiple daily injections in pediatric patients: one-year follow-up comparison by matched-pair analysis. Diabetes Care, 2006; 29:133–134.
15.
DanneT, BattelinoT, Jarosz-ChobotP, KordonouriO, PánkowskaE, LudvigssonJ, SchoberE, KaprioE, SaukkonenT, NicolinoM, Tubiana-RufiN, KlinkertC, HaberlandH, VazeouA, MadacsyL, ZangenD, CherubiniV, RabboneI, ToniS, de BeaufortC, Bakker-van WaardeW, van den BergN, VolkovI, BarrioR, HanasR, ZumstegU, KuhlmannB, AebiC, SchumacherU, GschwendS, HindmarshP, TorresM, ShehadehN, PhillipM. PedPump Study Group. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia, 2008; 51:1594–1601.
16.
BerghaeuserMA, KapellenT, HeidtmannB, HaberlandH, KlinkertC, HollRW. the DPV-Science-Initiative and the German Working Group for Insulin Pump Treatment in Pediatric Patients. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes, 2008; 9:590–595.
17.
DanneT, MortensenHB, HougaardP, LynggaardH, AanstootHJ, ChiarelliF, DanemanD, DorchyH, GarandeauP, GreeneSA, HoeyH, HollRW, KaprioEA, KocovaM, MartulP, MatsuuraN, RobertsonKJ, SchoenleEJ, SøvikO, SwiftPG, TsouRM, VanelliM, AmanJ. Hvidøre Study Group on Childhood Diabetes. Persistent differences among centers over 3 years in glycemic control and hypoglycaemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidøre Study Group. Diabetes Care, 2001; 24:1342–1347.
